gatifloxacin has been researched along with Pneumonia, Pneumococcal in 7 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Pneumonia, Pneumococcal: A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP)." | 2.70 | Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. ( Andes, DR; Ehrhardt, AF; Gothelf, S; Jones, RN; Mandell, LA; Nicholson, SC, 2002) |
| "Ertapenem is a promising new treatment for patients with pneumococcal pneumonia, including those at risk of infection with a fluoroquinolone-resistant strain." | 1.34 | Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia. ( Bast, DJ; De Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Walker, SE, 2007) |
| " The pharmacokinetic profiles also reflected the effectiveness of GFLX." | 1.32 | Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae. ( Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, RN | 1 |
| Andes, DR | 1 |
| Mandell, LA | 1 |
| Gothelf, S | 1 |
| Ehrhardt, AF | 1 |
| Nicholson, SC | 1 |
| Bello, S | 1 |
| Torres, A | 1 |
| Otsu, Y | 1 |
| Yanagihara, K | 2 |
| Fukuda, Y | 2 |
| Miyazaki, Y | 2 |
| Tsukamoto, K | 2 |
| Hirakata, Y | 2 |
| Tomono, K | 2 |
| Kadota, J | 2 |
| Tashiro, T | 2 |
| Murata, I | 2 |
| Kohno, S | 2 |
| Croisier, D | 1 |
| Etienne, M | 1 |
| Piroth, L | 1 |
| Bergoin, E | 1 |
| Lequeu, C | 1 |
| Portier, H | 1 |
| Chavanet, P | 1 |
| Hayashi, K | 1 |
| Kadowaki, SE | 1 |
| Takei, M | 1 |
| Fukuda, H | 1 |
| De Azavedo, JC | 1 |
| Dresser, L | 1 |
| Duncan, CL | 1 |
| Walker, SE | 1 |
| Low, DE | 1 |
| Bast, DJ | 1 |
1 trial available for gatifloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Community-Acquired Infe | 2002 |
6 other studies available for gatifloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mice; Mic | 2003 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Eva | 2004 |
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; DNA Gyrase; DNA Topoisomer | 2004 |
Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Lung; Mice; M | 2006 |
Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Disease Models, Animal; DNA Topoisomerase IV; Ertapene | 2007 |